ES2188985T3 - Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. - Google Patents

Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.

Info

Publication number
ES2188985T3
ES2188985T3 ES97942899T ES97942899T ES2188985T3 ES 2188985 T3 ES2188985 T3 ES 2188985T3 ES 97942899 T ES97942899 T ES 97942899T ES 97942899 T ES97942899 T ES 97942899T ES 2188985 T3 ES2188985 T3 ES 2188985T3
Authority
ES
Spain
Prior art keywords
enantiomeric
nucleic acids
evolution
selection
molecula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942899T
Other languages
English (en)
Inventor
Jens Peter Furste
Rolf Bald
Volker A Erdmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2188985T3 publication Critical patent/ES2188985T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ecology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tea And Coffee (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE EXPONE UN PROCEDIMIENTO PARA IDENTIFICAR Y PRODUCIR ACIDOS L-NUCLEICOS, QUE INTERACCIONAN CON UNA MOLECULA-BLANCO QUE TIENE UNA CONFIGURACION NATURAL, ASI COMO LOS ACIDOS LNUCLEICOS OBTENIDOS POR ESTE PROCEDIMIENTO. SE EXPONEN IGUALMENTE EL USO DE ACIDOS D-NUCLEICOS QUE SE FIJAN A LA ANTIPODA OPTICA DE LA MOLECULA-BLANCO COMO MATRIZ PARA PRODUCIR ACIDOS L-NUCLEICOS CON SECUENCIA IDENTICA, Y MEDICAMENTOS Y CONJUNTOS QUE CONTIENEN EL ACIDO L-NUCLEICO EXPUESTO.
ES97942899T 1996-08-30 1997-08-29 Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. Expired - Lifetime ES2188985T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96113953 1996-08-30

Publications (1)

Publication Number Publication Date
ES2188985T3 true ES2188985T3 (es) 2003-07-01

Family

ID=8223148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942899T Expired - Lifetime ES2188985T3 (es) 1996-08-30 1997-08-29 Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.

Country Status (8)

Country Link
US (1) US6605713B1 (es)
EP (1) EP0934331B1 (es)
JP (1) JP2001504448A (es)
AT (1) ATE228529T1 (es)
AU (1) AU743469C (es)
DE (1) DE59708838D1 (es)
ES (1) ES2188985T3 (es)
WO (1) WO1998008856A2 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2799465B1 (fr) * 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
US20050208487A1 (en) * 2000-05-26 2005-09-22 Jens Burmeister Immobilized nuckeic acids and uses thereof
DE10122862A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag GnRH bindende Nukleinsäure
DE10122847A1 (de) * 2001-05-11 2002-11-21 Noxxon Pharma Ag Enterotoxin B bindende Nukleinsäure
DK1264603T3 (da) * 2001-06-10 2010-04-26 Noxxon Pharma Ag Anvendelse af L-polynukleotider til in vivo-billeddannelse
EP1288309A1 (de) * 2001-08-30 2003-03-05 Noxxon Pharma AG Verfahren zur Markierung von L-Nukleinsäuren
EP1306382A1 (de) * 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ES2629615T3 (es) * 2001-10-26 2017-08-11 Noxxon Pharma Ag Ácido L-nucleico modificado
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
WO2003093504A1 (de) * 2002-05-06 2003-11-13 Noxxon Pharma Ag Verfahren zur amplifikation von nukleinsäuren
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
EP1386972A1 (en) * 2002-08-01 2004-02-04 Noxxon Pharma AG Method and apparatus for designing a nucleic acid having a desired property
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
WO2004035618A2 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
ATE420102T1 (de) 2002-10-18 2009-01-15 Silence Therapeutics Ag An der metastase beteiligter faktor und verwendungen dafür
EP2287311A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
CA2520868A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
EP2289907A3 (en) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP2992902A1 (en) 2004-12-27 2016-03-09 Silence Therapeutics GmbH Lipid complexes coated with peg and their uses
US20060199207A1 (en) * 2005-02-24 2006-09-07 Matysiak Stefan M Self-assembly of molecules using combinatorial hybridization
SG161311A1 (en) * 2005-05-04 2010-05-27 Noxxon Pharma Ag Novel use of spiegelmers
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
MX2008008548A (es) 2005-12-30 2008-09-10 Evonik Roehm Gmbh Peptidos utiles como petidos penetradores de celulas.
JP4984990B2 (ja) * 2006-03-28 2012-07-25 富士通株式会社 機能性分子の製造方法
EP2992875A1 (en) 2006-04-20 2016-03-09 Silence Therapeutics GmbH Lipoplex formulations for specific delivery to vascular endothelium
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CN102321626B (zh) 2006-07-21 2014-12-10 赛伦斯治疗有限公司 用于抑制蛋白激酶3表达的方法
EP2289906A1 (en) 2006-09-15 2011-03-02 Intercell AG Borrelia antigens
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
WO2008119571A2 (en) * 2007-01-03 2008-10-09 Novo Nordisk A/S Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
AU2008248755A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
US20100203075A1 (en) 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
EP2045326A1 (en) * 2007-10-05 2009-04-08 Bayer CropScience AG Method for identifying the interaction partner of an active agent
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009053691A1 (en) † 2007-10-22 2009-04-30 Pronota Nv Method of selecting aptamers
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
EP2393504B1 (de) * 2009-02-06 2013-06-05 Freie Universität Berlin Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
KR20130108983A (ko) 2010-05-26 2013-10-07 셀렉타 바이오사이언시즈, 인크. 커플링되지 않은 애주번트를 갖는 나노담체 조성물
WO2012022496A2 (en) 2010-08-19 2012-02-23 Per Sonne Holm Method for killing tumor stem cells
US20140056811A1 (en) 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
KR102080142B1 (ko) 2011-01-10 2020-02-21 아프타리온 바이오테크 아게 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법
EP2734531A1 (en) 2011-07-22 2014-05-28 Université de Strasbourg Phospholipid-detergent conjugates and uses thereof
EP2753697A1 (en) 2011-09-05 2014-07-16 ETH Zürich Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013050540A1 (en) 2011-10-05 2013-04-11 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
EP2785839A2 (en) 2011-11-30 2014-10-08 University of Bremen Expression of mirnas in placental tissue
JP2015521041A (ja) 2012-05-16 2015-07-27 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｋｎ３阻害剤投与のためのバイオマーカーとしてのｖｅｇｆｒ１の使用
ES2965777T3 (es) 2012-05-16 2024-04-16 Aptarion Biotech Ag Síntesis enzimática de ácidos L-nucleicos
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
EP2837939A1 (en) 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
EP3065744B1 (en) 2013-11-04 2021-04-21 Noxxon Pharma AG A ccl2 antagonist for use in treating proteinuria
KR20160079126A (ko) * 2013-11-20 2016-07-05 녹손 파르마 아게 효소를 통한 l-핵산의 합성
KR20160095003A (ko) 2013-12-05 2016-08-10 사일런스 테라퓨틱스 게엠베하 폐 특이적 전달을 위한 수단
CN114716555A (zh) 2014-01-10 2022-07-08 博笛生物科技有限公司 靶向表达egfr的肿瘤的化合物和组合物
CA2937447A1 (en) 2014-01-29 2015-08-06 Vaxine Pty Ltd New target for diabetes treatment and prevention.
ES2796090T3 (es) 2014-02-10 2020-11-25 Inst Curie Uso de moduladores MCOLN-1 para regular la migración celular
AU2015286043B2 (en) 2014-07-09 2020-08-20 Birdie Biopharmaceuticals Inc. Anti-PD-L1 combinations for treating tumors
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3000483A1 (en) 2014-09-29 2016-03-30 Charité - Universitätsmedizin Berlin Means and methods for the diagnosis and treatment of neurodegenerative diseases
WO2016196218A1 (en) 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy
EP3264092A1 (en) 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
EP3315125A1 (en) 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
EP3555138A1 (en) 2016-12-16 2019-10-23 Université de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
EP3521828A1 (en) 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
CA3092907A1 (en) 2018-03-05 2019-09-12 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
CA3149497A1 (en) 2019-08-09 2021-02-18 Nutcracker Therapeutics, Inc. Methods and apparatuses for manufacturing for removing material from a therapeutic composition
AU2020342594A1 (en) 2019-09-05 2022-03-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a CDK4/6 inhibitor and a further therapeutically active agent
AU2020407285A1 (en) 2019-12-20 2022-08-11 CureVac SE Lipid nanoparticles for delivery of nucleic acids
AU2022336209A1 (en) 2021-09-03 2024-01-18 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505527A (ja) 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
GB9609722D0 (en) 1996-05-09 1996-07-10 Smithkline Beecham Corp Novel method

Also Published As

Publication number Publication date
DE59708838D1 (de) 2003-01-09
JP2001504448A (ja) 2001-04-03
EP0934331A2 (de) 1999-08-11
AU743469C (en) 2004-02-12
EP0934331B1 (de) 2002-11-27
WO1998008856A2 (de) 1998-03-05
US6605713B1 (en) 2003-08-12
WO1998008856A3 (de) 1998-05-07
AU4456897A (en) 1998-03-19
AU743469B2 (en) 2002-01-24
ATE228529T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
ES2188985T3 (es) Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.
ES2000015T3 (es) Superficies polimericas modificadas y metodo de preparacion de las mismas.
DE69016097D1 (de) Entladungslampe mit Verwendung von akustischen Resonanzschwingungen zur Sicherstellung eines hohen Wirkungsgrades.
ES2105999T3 (es) Procedimiento para la preparacion industrial de fosfatidilserina.
ATE282176T1 (de) Beleuchtungsvorrichtung für nicht-emitierende anzeige
AR031185A1 (es) Casquillo de empalme interacoplable, de baja perdida, para fibras opticas y un metodo para la fabricacion de este
ES2186690T3 (es) Acido nucleico enzimatico que contiene no-nucleotidos.
ES2068202T3 (es) Composicion liquida suavizante para prendas de ropa.
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
ES2133650T3 (es) Acristalamiento de aviones con estabilidad a la luz, estabilidad quimica y estabilidad dimensional bajo calor.
EA199900580A1 (ru) Фармацевтические производные аминофосфоновой кислоты
ES2102312B1 (es) Procedimiento para la cristalizacion del iopamidol
ES2104766T3 (es) Agentes tensioactivos derivados de esteres de acido sulfosuccinico.
ES2139143T3 (es) Gel micro-mesoporoso y procedimiento para su preparacion.
SE9901306D0 (sv) Improved TIRF chamber
ES493536A0 (es) Procedimiento para revestir una caja catodica que tiene una pluralidad de catodos foraminados con cavidad, con un dia- fragma sintetico.
EA199900842A1 (ru) Модуляторы функции рецепторов, принадлежащих к семейству рецепторов tnf/ngf
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
ES2057861T3 (es) Medio de almacenamiento de datos y metodos para registrar y leer datos.
EA200000069A1 (ru) Способ получения 4-замещенных-1h-индол-3-глиоксамидов
ES2022865B3 (es) Compuestos azoicos que contienen grupos ciano, procedimientos para su obtencion y aplicacion de los mismos como colorantes.
IT7829874A0 (it) Cementi rinforzati con fibre di vetro e processo per la loro fabbricazione.
ES2038118T3 (es) Procedimiento para producir una disposicion de promotores, que son activos en estreptomicetos.
DK679387A (da) Indikatorlampe til indstoebning i beton eller lignende
BR9709564A (pt) Processo para produzir compostos alifaticos de mais baixo teor de enxofre e uso de um extrator morfolinico